102 results about "Umbilical vein" patented technology

A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD / SCID immunodeficient mouse transplant system.

The invention relates to a separation method and a culture method for umbilical cord mesenchymal stem cells. The separation method comprises the following steps: thoroughly cleaning umbilical cord tissue of a healthy newborn by using a PBS (phosphate buffer solution) containing streptomycin and penicillin, and removing blood; shearing the umbilical cord into small sections uniform in length, and mechanically separating, bluntly stripping Wharton' s jelly, and removing umbilical arteries and umbilical veins; uniformly shearing the Wharton' s jelly; re-suspending the sheared Wharton' s jelly through an MSCs (mesenchymal stem cells) culture medium, inoculating to a culture dish with laid gelatin, and putting in a CO2 culture box for cultivation; conducting centrifugal separation to obtain tissue blocks and a cell resuspension solution. The culture method comprises the following steps: enwrapping the culture dish, discarding the gelatin, and washing with the PBS; inoculating the separated out tissue blocks and the cell resuspension into the culture dish; performing digestive subculture after cell fusion growth rate reaches 80-90%.

The invention provides a preparation method of clinical application-level placental hematopoietic stem cells. The preparation method comprises the steps of pretreating a fresh delivered placenta immediately and then separating out umbilical arteries and umbilical veins, pouring a cleaning fluid into the chorionic vessels of the placenta and colleting the cleaning fluid after pouring, pouring an enzyme digestion fluid into the chorionic vessels of the placenta and digesting at 37 DEG C for 5-20min, pouring the collected fluid into the placenta and collecting the liquid after pouring, centrifuging the obtained fluid and re-suspending cells after removing the supernatant, and separating the resuspended cell suspension through a two-step process with hydroxyethyl starch and a lymphocyte separation medium to obtain the clinical application-level placental hematopoietic stem cells. The method is capable of increasing the number and the activity of the prepared placental hematopoietic stem cells and the content of CD34 positive cells, and the prepared placental hematopoietic stem cells are at the clinical application level and free of potential pathogenic contamination, and moreover, the method is low in preparation cost.

By use of hybridoma technology, recombinant human Delta like 4 (rhDll4) is used as an antigen for immunizing a BALB / c mice to obtain a high affinity and biological activity anti-human Delta like 4 monoclonal antibody. The monoclonal antibody is characterized in that: the monoclonal antibody can be combined with rhDll4 specifically, and can block human umbilical vein endothelial cells (HUVEC) proliferation suppression of the rhDll4. Specifically, screening, a preparation method, and nucleotide and amino acid sequences of the heavy chain variable region and the light chain variable region of the anti-human Delta like 4 monoclonal antibody are disclosed, and the nucleotide and amino acid sequences comprise nucleotide and amino acid sequences corresponding to complementarity determining regions CDR1, CDR2 and CDR3.

The invention relates to the field of cell engineering and discloses mesenchymal stem cells, as well as a preparation method and an application thereof. The method comprises the following steps of cutting an umbilical cord into small pieces after removing an umbilical artery and umbilical veins, digesting with an alpha MEM (minimum essential medium) culture medium containing 0.1% of type IV collagenase and a complete medium, then centrifugating cell suspension obtained after digestion, removing supernatant liquid, then washing, further performing resuspension with the complete medium, transferring suspension after resuspension into a culture bottle coated by a wall-adhered matrix for culture till the emergence of shuttle-shaped wall-adhered cells, washing, and replacing the new complete medium for continuing the culture so as to get the shuttle-shaped wall-adhered cells after the culture, namely the mesenchymal stem cells. According to the preparation method disclosed by the invention, the culture medium without serum or foreign protein is used for preparation, a recombinase with a single component is used for passage, and the prepared mesenchymal stem cells are smaller in diameter, have no sensibiligen and can improve the vitality of the cells and increase the safety in regeneration treatment of a patient.

The invention discloses a method and application for promoting cells to secrete exosomes, and relates to the fields of biological materials, tissue engineering and regenerative medicines. According tothe method, the cells are stimulated by active signals of a biological material, and the exosomes generated by the cells are collected, and are used for tissue wound treatment. The operation route ofthe method and the application scheme of the obtained exosomes are described in detail, under the stimulation effects of bioactive glass chemical signals, electrostatic spinning fiber membrane structure signals and chemical / structural combination signals, more exosome particles can be secreted by mesenchymal stem cells and umbilical vein endothelial cells, and the exosomes can promote the corresponding target cells to express higher levels of functional genes, secrete more multifunctional proteins and carry out deep functional differentiation, so that the tissue wound surface can be rapidly repaired. The exosomes obtained by the method disclosed by the invention have the characteristics of higher yield and stronger tissue repair promotion function.

The invention discloses a polypeptide molecule exerting selective killing and migration inhibiting effect on cancer cells, and a design method and application thereof, belonging to the technical field of application of biopharmacy. The polypeptide molecule comprises a polypeptide amino acid sequence and constituent (SEQ ID No. 1) and contains altogether 12 amino acids. Through 9R or 8R coupling reconstruction and designing, the polypeptide molecule has strong killing effect on malignant cells of human liver cancer, prostatic cancer, breast cancer and the like and low killing effect on normal human hepatic cells, embryonic kidney cells and umbilical vein endothelial cells; in particular, the polypeptide molecule has strong selective killing effect on liver cancer cells and inhibitory effect on migration of human liver cancer and umbilical vein endothelial cells compared with normal human hepatic cells. The polypeptide molecule is mainly applied to preparation of drugs used for selective killing and migration inhibiting of malignant cells of human liver cancer.

The invention discloses a vascular endothelial cell and a preparation method and application thereof; the method for separating the vascular endothelial cell disclosed by the invention comprises the following steps: II type collagenase is used for digesting umbilical vein of umbilical cord in vitro, cells are collected, then culture is carried out and adherent cells are obtained, namely the vascular endothelial cell. The separation method of the invention has simple operation and convenience and practicability; the obtained vascular endothelial cell has high purity, large amount, strong exogenic propagation and a plurality of times of passage, and not only has the functions of phagotrophy and tube formation, but also has the function of inhibiting progenitor cells to develop into dendritic cells; therefore, the invention establishes a stable technical system for the separation and culture of the vascular endothelial cell and lays the foundation for the study and the application of the endothelial cell.

A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided. The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.

The invention discloses gramicidin, isomer thereof and application thereof. The structure is Ac-Asp-Arg-Val-Tyr-Ile-His-Pro-NH2 and Ac-Asp-Arg-Val-Tyr(D)-Ile-His(D)-Pro. Two modified construction bodies have biological activity which is similar to angiotensin 1-7 and capable of promoting human umbilical vein endothelial cells (HUVEC) to release nitrogen oxide (NO) for migration, forming a tubelet and restraining A549 cell growth. Simultaneously, the modified construction bodies have degradation capability of three degradation enzymes including ACE, NEP and AP, thereby ensuring that the modified construction bodies have longer half-life periods than the angiotensin 1-7. The modified construction bodies are simple to obtain and provide important application value for development of novel polypeptide drugs for treating cardiovascular and cerebrovascular diseases.

A heparan sulfated derivative is prepared from heparan sulfated by sulphating. A preparation method comprises: swelling heparan sulfated by anhydrous dimethyl formamide, adding a sulfur trioxide-trimethylamine complex, heating for esterification, dissolving, dialyzing, freeze-drying precipitation components of the reactant by distilled water, then dissolving by sodium chloride solution, precipitating by ethanol, centrifuging, removing a supernatant, drying, and then obtaining sulphated heparan sulfated. The heparan sulfated derivative can inhibit activities of tumor cells and umbilical vein endothelial cell proliferation.

The invention discloses application of TTR (transthyretin) to angiogenesis inhibition, and belongs to the fields of biochemistry, molecular biology and medicine. After the TTR is given to mammals, inSTZ induced diabetes rat and mouse models, the new vessels of eyes are obviously reduced. Tumor new vessel, diabetes new vessel, eye new vessel and brain new vessel in vitro experiment models verify that the TTR has the effect of inhibiting the angiogenesis; the result shows that the TTR can act on an in vitro cell model in anoxic environment of brain and can continuously and efficiently inhibit the generation of new vessels. When the TTR acts on endothelial cells of umbilical veins, the formation of 90 percent of vessels can be obviously inhibited; when the TTR acts on endothelial cells of cerebral microvessel, the formation of 95 percent of vessels can be effectively inhibited; when the TTR acts on the endothelial cells of eye microvessel, the formation of 90 percent of vessels can be effectively inhibited; when the TTR acts on rat and mouse models, the as high as generation of 90 percent of new vessels can be effectively inhibited.

The invention relates to NuBCP-9 and Tumstatin(74-98) fusion genetic engineering antitumor peptide which is designed to be synthetic primer according to colon bacillus favorable codon, NuBCP-9 and Tumstation(74-98) fusion peptide gene order connected by flexible peptide (G4S3) is obtained by PCR through an SOE method, the NuBCP-9 and Tumstation(74-98) fusion peptide forms recombination expression plasmid after connecting with a carrier Pet 32A(+), the recombination expression plasmid is transferred to colon bacillus BL21 for performing the soluble efficient expression and purifying and enzyme-cutting to obtain the purpose peptide. The fusion peptide has better inhibition function to skin cell proliferation in umbilical vein and lung cancer cell, primarily shows the multitarget antitumor effect, and can have better clinical application prospect.

The invention relates to a myxobacteria strain and an antitumor activity metabolite thereof. The myxobacteria strain is the myxococcus STXZ72, Myxococcus sp.STXZ72, and the preservation number of the strain is CCTCC NO:M2015353. The invention further comprises a separation and purification method of the antitumor activity metabolite of myxobacteria. The metabolite of Myxococcus sp.STXZ72 is prepared by utilizing the separation and purification method. Antitumor activity determination proves that the myxobacteria strain is capable of effectively inhibiting the activity of a variety of tumor cells and also has very low toxicity to normal human umbilical vein endothelial cells.

The present invention provides a dilator for umbilical vein puncture. The dilator for the umbilical vein puncture comprises a hand-held portion and a first extension member, one end of the first extension member is a first insertion section for inserting an umbilical vein, the other end of the first extension member is connected with the hand-held portion, and the first insertion section is a structure with a radial-direction size gradually increased from an end portion away from the hand-held portion to a direction connected with the hand-held portion; and a first insertion groove is arrangedin the first insertion section and used for insertion of an intubation tube for the umbilical vein. In the provided dilator for the umbilical vein puncture, the end portion of the insertion section is relatively small and convenient for insertion into the umbilical vein, then the structure with the gradually increased radial-direction size opens the umbilical vein, and then the intubation tube isinserted into the umbilical vein along the first insertion groove, thereby greatly facilitating the operation of the insertion of the intubation tube into the umbilical vein, reducing operation difficulty of operations and saving time.

The invention belongs to the field of gene engineering technology, and provides a small interfering RNA specifically inhibiting annexin A2 acceptor, and application of the siRNA to prepare medicines for treating neovascular diseases. Experiments prove that the siRNA aiming at AXIIR gene expression is capable of inhibiting propagation, migration and blood vessel formation of umbilical vein endothelial cells, and inducing retardance of cell cycle. The siRNA is applicable to prepare stable effective low-toxicity biological targeting preparations or medicines for inhibiting AXIIR expression and treating neovascular diseases.

The invention belongs to the technical field of biological product separation culture, and particularly relates to a human umbilical cord mesenchymal stem cell separation culture method. The method comprises the following steps that an in-vitro umbilical cord of a term fetus born by caesarean delivery is taken and put into a sterile tissue preserving fluid for storage; flushing is conducted multiple times with normal saline, and remained bloodstains are removed; two umbilical veins and two umbilical arteries of tissue mass are removed with toothed tweezers, and Wharton's jelly is completely cut into pieces with sterile scissors; the Wharton's jelly which is cut into pieces is transferred into a culture medium, and vibration and centrifugation are conducted in sequence; the centrifugal sedimentation part is transferred into a cell culture flask; after culture is conducted for 5-6 days, it can be seen that part of cells climb out from the periphery of small pieces of the tissue, then a culture substrate is replaced once every three days, and culture continuous to be conducted; on the fourteenth day or so, the degree of cell fusion reaches 80% or above, and spiral growth is achieved;afterwards, each transmission of the next generation takes three days, and adequate mesenchymal stem cells can be obtained. Compared with a traditional tissue method, the method is simpler, and the purity and yield of stem cells are higher.

The present invention discloses method of inducing antitumor immunity and its application in preparing medicine. The method is to induce antitumor immunity with live myeloma FO cell, freeze dried powder of GM-CSF transfected myeloma FO cell, primary human umbilical vein vessel endothelial cell, or the extract of tumor vessel endothelial cell membrane surface protein. The method may be used in preparing antitumor medicine and has simple operation and high antitumor immunity inducing effect.

The invention belongs to the field of medical teaching appliances, and relates to a teaching model used for antenatal diagnosis paracentesis training. The model comprises a model body, an assembly mechanism and an observation mechanism, wherein the model body comprises a uterus model body, a bracket, an inferior belly model body, a superior belly model body, an umbilical cord model body and a uterine cake model body. The teaching model used for antenatal diagnosis paracentesis training has the advantages that various paracentesis operation processes in the antenatal diagnosis can be simulated,so that a practicer can really master chorionic villi sampling, amniocentesis, umbilical veins paracentesis and other pregnancy check-up paracentesis training.

The invention relates to an externally applied traditional Chinese medicine composition for treating umbilical hernia and an umbilical hernia treating bag containing lychee seed and rhizoma cimicifugae. The traditional Chinese medicine composition is prepared from radix astragali, angelica, bighead atractylodes rhizome, rhizoma cimicifugae, radix bupleuri, dried orange peel, toosendan fruit, Evodia rutaecarpa, lychee seed, fennel, clove, asarum, safflower and the like. The umbilical hernia treating bag comprises a bellyband body and fastening belts, wherein the inner side of the bellyband body is provided with a square or circular inner bag, and a medicine core pad containing the traditional Chinese medicine composition is filled in the inner bag. In the invention, traditional Chinese medicines with the functions of tonifying middle-Jiao and qi, soothing the liver and strengthening the spleen are used for umbilical skin absorption and physical support for treating infantile umbilical hernia. By utilizing the externally applied traditional Chinese medicine composition, the defect of long treatment course in self-recovery and conservative treatment of umbilical hernia and the defect that the sick children can feel painful in the operative treatment are solved. The invention has the characteristics of obvious curative effect and short treatment course, and the patients can not feel painful and have no skin irritation symptom or anaphylaxis. The invention is suitable for children with tender viscera, is also suitable for clinical features of children, and can promote the children with umbilical hernia to grow up healthily. The raw materials in the prescription are conventional traditional Chinese medicines, thus, the invention has the advantages of wide raw material sources, low cost and simple technique, and is easy for popularization.

The invention provides a method for preparing recombinant protein of a human vascular endothelial cell-growth inhibiting factor rhVEGI-192A. The method comprises the steps of using a nucleotide sequence of VEGI-192A gene coding to construct an expression vector and inducing the expression vector to express in a host cell. Particularly, total RNA of human umbilical vein vascular endothelial cell line HUVEC is amplified to obtain a VEGI-192A gene fragment; a target gene is obtained through digestion by use of restriction endonuclease double enzyme; the target gene is connected to the expressionvector pET-30a to construct a recombinant protein expression vector; and the recombinant protein expression vector is transformed into escherichia coli host bacteria to induce expression so as to obtain purified protein. The method has the advantages of building a target-protein prokaryotic expression system with high efficiency, high yield, high activity and high purity on the basis of maintaining the natural spatial conformation of rhVEGI-192 recombinant protein, optimizing expression conditions and building a method for separating, purifying and renaturing target products.

The invention discloses a stem cell exosome preparation. The stem cell exosome preparation comprises mesenchymal stem cell exosome, umbilical vein endothelial cells, human serum albumin and normal saline, wherein the mesenchymal stem cell exosome is exosome extracted from human umbilical cord mesenchymal stem cells. The invention also discloses a preparation method of the stem cell exosome preparation. The method comprises the following steps: S1, culturing human umbilical cord mesenchymal stem cells; S2, preparing the mesenchymal stem cell exosome; and S3, preparing the stem cell exosome preparation. The stem cell exosome preparation is prepared by adding the mesenchymal stem cell exosome and the umbilical vein endothelial cells into a human serum albumin solution, the obtained exosome preparation can remarkably improve the proliferation and migration capacity of the umbilical vein endothelial cells and promote generation of blood vessels, and compared with cell therapy, the exosome is more stable in property. and more convenient to store and transport; and the exosome is extracted by adopting a traditional differential ultracentrifugation method, so that the purity is relatively high, and the cost is relatively low.

The invention discloses a method for preparing cancer cell targeted cell-like micro-capsules. Endothelial cells of human umbilical veins are used as raw materials for preparing cell-like micro-capsules with amino groups on surfaces, and the micro-capsules are dispersed in an aptamer solution containing aldehyde groups; after a certain period of incubation, aptamers are marked on the surfaces of the cell-like micro-capsules and then washed with a phosphate buffer solution; and the processed cell-like micro-capsules are immersed into a drug solution of doxorubicin hydrochloride, drugs are loaded through electrostatic interaction, and finally, the cell-like micro-capsules different in drug loading capacity are obtained. The preparation method is simple, controllable, wide in material source, high in production efficiency, capable of adjusting the drug loading capacity of the cell-like micro-capsules conveniently and providing the characteristics of target cancer cells simultaneously and good in application prospect.

The invention relates to a preparation method of an oyster shell extract. The method comprises the following steps of: adding water-containing solution of alcohol into oyster shell powder in a material to liquid ratio of 1g:2-20mL, performing reflux extraction and filtering or centrifugally separating liquid out; and concentrating the obtained liquid under reduced pressure, extracting with an organic solvent, separating an organic solvent layer out, concentrating under reduced pressure and drying to obtain the oyster shell extract. Tests by a lissamine rhodamine B method indicate that the prepared oyster shell extract has the function of inhibiting cell proliferation of a plurality of tumor cell strains; and tests by a methyl thiazolyl tetrazolium method indicate that the oyster shell extract has the function of inhibiting cell proliferation of human umbilical vein endothelial cells. Experiments indicate that the oyster shell extract can play a role in resisting tumors by inhibiting tumor cell proliferation and angiogenesis. Therefore, the oyster shell extract of the invention can be taken as a cell proliferation inhibitor, an angiogenesis inhibitor and an anti-tumor agent.

The invention discloses a dialysis membrane material having a physiological function and a preparation method for the same. According to the invention, a TiO2 nanotube array film permeable at two ends is used as a substrate, and renal tubular epithelial cells and umbilical vein endothelial cells are mixedly planted on the film so as to endow the film with a physiology function. The TiO2 nanotube array film is applied in dialysis membrane materials for the first time; since the TiO2 nanotube array film has good blood compatibility, photocatalysis, hydrophilicity and self-cleaning capability, disadvantages of conventional polysulfone membranes are overcome, and requirements for membrane materials for hemodialyzers are well met. The dialysis membrane material having the physiological function prepared by the method can fulfill the functions of kidney tubules and glomerulus, enables an apparatus to be simplified and is favorable for construction of miniaturized biological artificial kidneys. The material is widely used in biomedical fields, e.g., separation of proteins, bioactive filtration, diffusion of high-molecular weight substances, filtration of molecules, conveying of drugs, etc.

Provided is a peptide, which has an anti-inflammatory activity and an activity for promoting osteogenic differentiation, formed from the amino acid sequence selected from the group comprising the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. And provided is a peptide, which has a hair growth promoting activity, formed from the amino acid sequence selected from the group comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. A peptide formed from the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, according to the present invention, consequently shows an anti-inflammatory activity by inhibiting an inflammatory cytokine expression and proliferation of inflammatory cells, and consequently promotes osteogenic differentiation by increasing phosphorylation of PI3K, Smad1, Smad5 and Smad8, which contribute to osteogenesis, and by increasing ALP, OPG and BSP expressions. And a peptide formed from the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, according to the present invention, consequently shows efficacy for preventing hair loss and promoting hair growth by promoting proliferation of hair follicle cells and human umbilical vein endothelial cells, increasing phosphorylation of EPK, increasing expressions of PI3K, β-catenin, IGF-1, KGF and Wnt3a which are proteins that contribute to hair growth, and reducing an expression of DKK-1 which is a hairless gene.

The invention relates to the technical field of umbilical artery and vein catheter fixing operation, and discloses a novel bridge type fixing method for an umbilical artery and vein catheter of a newborn baby. Required appliances for the fixing method comprise punching forceps, a hydrocolloid dressing and scissors, wherein the punching forceps are provided with a cutting die, protecting paper is arranged on one of the surfaces of the hydrocolloid dressing; and the umbilical artery and vein catheter is arranged at the position of an umbilical region of the newborn baby in advance. The bridge type fixing method comprises the following operation steps: (1) appliance preparation, (2) opening selection, (3) dressing cutting, (4) adhesion fixing, and (5) umbilical position covering. The umbilical artery and vein catheter can be fixed easily, the method is simple and convenient to operate, a sterile operation barrier is expanded, cleaning and sterilizing of a rear umbilical part of the umbilical artery and vein catheter are facilitated, the skin of the newborn baby can further be prevented from being injured effectively, and therefore, the effect of the umbilical artery and vein catheter is ensured.

The invention discloses a method for extracting umbilical cord mesenchymal stem cells by combining grinding with mixed enzyme. The method comprises the steps of 1, removing both ends of the umbilicalcord, and washing arteriovenous blood stains of the umbilical cord; 2, removing umbilical arteries and umbilical veins, cutting the umbilical cord into small pieces, peeling off an adhesive layer, cutting it into smaller pieces; 3, splitting and charging the tissue pieces into a centrifuging tube, and grinding the tissue into meat paste with a tissue grinder; 4, mixing collagenase and trypsin witha meat paste suspension and shaking the mixture in a shaker; 5, after neutralizing with a culture medium, centrifuging supernatant, mixing with a culture solution is executed, and adding the mixtureinto a cell culture flask; 6, standing and culture, digesting with enzyme, and then executing subculture; 7, continuing to culture for a period of time, subculturing P1 generation and cryopreserving the P2 generation. Based on the method of combining tissue grinding with digestion, the yield of primary cells can be greatly improved, and cell damage can be decreased.